-
1دورية أكاديمية
المؤلفون: Cherenko, M, Appelman-Dijkstra, NM, Priego Zurita, AL, Biermasz, NR, Dekkers, OM, Klok, FA, Reisch, N, Aulinas, A, Biagetti, B, Cannavo, S, Canu, L, Detomas, M, Devuyst, F, Falhammar, H, Feelders, RA, Ferrau, F, Gatto, F, Grasselli, C, van Houten, P, Hoybye, C, Isidori, AM, Kyrilli, A, Loli, P, Maiter, D, Nowak, E, Pivonello, R, Ragnarsson, O, Steenaard, RV, Unger, N, van de Ven, A, Webb, SM, Yeste, D, Ahmed, SF, Pereira, AM
المصدر: Endocrine connections. 13(6)
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Bothou, C, Anand, G, Li, DF, Kienitz, T, Seejore, K, Simeoli, C, Ebbehoj, A, Ward, EG, Paragliola, RM, Ferrigno, R, Badenhoop, K, Bensing, S, Oksnes, M, Esposito, D, Bergthorsdottir, R, Drake, W, Wahlberg, J, Reisch, N, Hahner, S, Pearce, S, Trainer, P, Etzrodt-Walter, G, Thalmann, SP, Saevik, AB, Husebye, E, Isidori, AM, Falhammar, H, Meyer, G, Corsello, SM, Pivonello, R, Murray, R, Bancos, I, Quinkler, M, Beuschlein, F
المصدر: The Journal of clinical endocrinology and metabolism. 105(8):E2853-E2863
مصطلحات موضوعية: Medicin och hälsovetenskap
-
3دورية أكاديمية
المؤلفون: Cherenko, M., Appelman-Dijkstra, N.M., Priego Zurita, A.L., Biermasz, N.R., Dekkers, O.M., Klok, F.A., Reisch, N., Aulinas, A., Biagetti, B., Cannavo, S., Canu, L., Detomas, M., Devuyst, F., Falhammar, H., Feelders, R.A., Ferrau, F., Gatto, F., Grasselli, C., van Houten, P., Hoybye, C., Isidori, A.M., Kyrilli, A., Loli, P., Maiter, D., Nowak, E., Pivonello, R., Ragnarsson, O., Steenaard, R.V., Unger, N., van de Ven, A., Webb, S.M., Yeste, D., Ahmed, S.F., Pereira, A.M.
الوصف: Background: Patients with Cushing syndrome (CS) are at increased risk of venous thromboembolism (VTE). Objective: The aim was to evaluate the current management of new cases of CS with a focus on VTE and thromboprophylaxis. Design and methods: A survey was conducted within those that report in the electronic reporting tool (e-REC) of the European Registries for Rare Endocrine Conditions (EuRRECa) and the involved main thematic groups (MTG’s) of the European Reference Networks for Rare Endocrine Disorders (Endo-ERN) on new patients with CS from January 2021 to July 2022. Results: Of 222 patients (mean age 44 years, 165 females), 141 patients had Cushing disease (64%), 69 adrenal CS (31%), and 12 patients with ectopic CS (5.4%). The mean follow-up period post-CS diagnosis was 15 months (range 3–30). Cortisol-lowering medications were initiated in 38% of patients. One hundred fifty-four patients (69%) received thromboprophylaxis (including patients on chronic anticoagulant treatment), of which low-molecular-weight heparins were used in 96% of cases. VTE was reported in six patients (2.7%), of which one was fatal: two long before CS diagnosis, two between diagnosis and surgery, and two postoperatively. Three patients were using thromboprophylaxis at time of the VTE diagnosis. The incidence rate of VTE in patients after Cushing syndrome diagnosis in our study cohort was 14.6 (95% CI 5.5; 38.6) per 1000 person-years. Conclusion: Thirty percent of patients with CS did not receive preoperative thromboprophylaxis during their active disease stage, and half of the VTE cases even occurred during this stage despite thromboprophylaxis. Prospective trials to establish the optimal thromboprophylaxis strategy in CS patients are highly needed. Significance statement: The incidence rate of venous thromboembolism in our study cohort was 14.6 (95% CI 5.5; 38.6) per 1000 person-years. Notably, this survey showed that there is great heterogeneity regarding time of initiation and duration of thromboprophylaxis in expert centers ...
وصف الملف: text
العلاقة: https://eprints.gla.ac.uk/327679/1/327679.pdfTest; Cherenko, M. et al. (2024) Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey. Endocrine Connections , 13(6), e240046. (doi:10.1530/ec-24-0046 ) (PMID:38614126) (PMCID:PMC11103746)
-
4دورية أكاديمية
المؤلفون: Arosio, M., Sciannameo, V., Contarino, A., Berchialla, P., Puglisi, S., Pesatori, A. C., Ferrante, E., Filopanti, M., Pivonello, R., Dassie, F., Rochira, V., Cannavò, S., De Menis, E., Pigliaru, F., Grottoli, S., Cambria, V., Faustini-Fustini, M., Montini, M., Peri, A., Ceccato, F., Puxeddu, E., Borretta, G., Bondanelli, M., Ferone, D., Colao, A., Terzolo, M., Reimondo, G.
المساهمون: Ministero della Salute, Regione Lombardia, Università degli Studi di Milano
المصدر: Journal of Endocrinological Investigation ; ISSN 1720-8386
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism
الوصف: Objective This study aimed to assess the long-term outcome of patients with acromegaly. Design This is a multicenter, retrospective, observational study which extends the mean observation period of a previously reported cohort of Italian patients with acromegaly to 15 years of follow-up. Methods Only patients from the centers that provided information on the life status of at least 95% of their original cohorts were included. Life status information was collected either from clinical records or from the municipal registry offices. Standardized mortality ratios (SMRs) were computed comparing data with those of the general Italian population. Results A total of 811 patients were included. There were 153 deaths, with 90 expected and an SMR of 1.7 (95% CI 1.4–2.0, p < 0.001). Death occurred after a median of 15 (women) or 16 (men) years from the diagnosis, without gender differences. Mortality remained elevated in the patients with control of disease (SMR 1.3, 95% CI 1.1–1.6). In the multivariable analysis, only older age and high IGF1 concentrations at last available follow-up visit were predictors of mortality. The oncological causes of death outweighed the cardiovascular ones, bordering on statistical significance with respect to the general population. Conclusions Mortality remains significantly high in patients with acromegaly, irrespectively of disease status, as long as the follow-up is sufficiently long with a low rate of patients lost to follow-up. Therapy strategy including radiotherapy does not have an impact on mortality. Oncological causes of death currently outweigh the cardiovascular causes.
-
5دورية أكاديمية
المؤلفون: Pivonello, C., Patalano, R., Simeoli, C., Montò, T., Negri, M., Amatrudo, F., Di Paola, N., Larocca, A., Crescenzo, E. M., Pirchio, R., Solari, D., de Angelis, C., Auriemma, R. S., Cavallo, L. M., Colao, A., Pivonello, R.
المساهمون: Ministero dell'Università e della Ricerca, Regione Campania, Università degli Studi di Napoli Federico II
المصدر: Journal of Endocrinological Investigation ; ISSN 1720-8386
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism
الوصف: Purpose Impairment of skeletal muscle mass and strength affects 40–70% of patients with active Cushing’s syndrome (CS). Glucocorticoid excess sustains muscle atrophy and weakness, while muscle-specific microRNAs (myomiRs) level changes were associated with muscle organization and function perturbation. The aim of the current study is to explore changes in circulating myomiRs in CS patients compared to healthy controls and their involvement in IGFI/PI3K/Akt/mTOR pathway regulation in skeletal muscle. Methods C2C12, mouse myocytes, were exposed to hydrocortisone (HC), and atrophy-related gene expression was investigated by RT-qPCR, WB and IF to assess HC-mediated atrophic signalling. miRNAs were evaluated in HC-treated C2C12 by PCR Arrays. MyomiRs significantly overexpressed in C2C12 were investigated in 37 CS patients and 24 healthy controls serum by RT-qPCR. The anti-anabolic role of circulating miRNAs significantly upregulated in CS patients was explored in C2C12 by investigating the IGFI/PI3K/Akt/mTOR pathway regulation. Results HC induced higher expression of atrophy-related genes, miR-133a-3p, miR-122-5p and miR-200b-3p in C2C12 compared to untreated cells. Conversely, the anabolic IGFI/PI3K/Akt/mTOR signalling was reduced and this effect was mediated by miR-133a-3p. In CS patients miR-133a-3p and miR-200b-3p revealed higher circulating levels ( p < 0.0001, respectively) compared to controls. ROC curves for miR-133a-3p (AUC 0.823, p < 0.0001) and miR-200b-3p (AUC 0.850, p < 0.0001) demonstrated that both myomiRs represent potential biomarkers to discriminate between CS and healthy subjects. Pearson’s correlation analysis revealed that circulating levels of miR-133a-3p are directly correlated with 24 h urinary-free cortisol level ( r = 0.468, p = 0.004) in CS patients. Conclusions HC induces atrophic signals by miR-133a-3p overexpression in mouse myocytes and humans. Circulating miR-133a-3p is promising biomarkers of hypercortisolism.
-
6دورية أكاديمية
المؤلفون: Pivonello, R., Scaroni, C., Polistena, B., Migliore, A., Giustina, A.
المساهمون: Recordati Rare Diseases, Università degli Studi di Napoli Federico II
المصدر: Journal of Endocrinological Investigation ; volume 46, issue 9, page 1923-1934 ; ISSN 1720-8386
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism
الوصف: Background Cushing’s syndrome (CS) is a rare clinical condition caused by excessive cortisol secretion from adrenal glands. CS is associated with increased mortality and morbidity; therefore, a prompt diagnosis and an effective therapeutic approach are strongly necessary to improve the patient’s clinical management. The first-line treatment for CS is surgery, while medical treatment has historically played a minor role. However, thanks to the availability of novel compounds, the possibility of improving hypercortisolism control using different drug combinations emerged. Purpose No absolute recommendations are available to guide the therapeutic choice for patients with CS and, consequently, the awareness of unmet needs in CS management is growing. Although new data from clinical trials are needed to better define the most appropriate management of CS, an expert consensus approach can help define unmet needs and optimize the current CS management and treatment. Methods Twenty-seven endocrinologists from 12 Italian regions, working among the main Italian referral centers for hospital endocrinology where they take care of CS patients, were involved in a consensus process and used the Delphi method to reach an agreement on 24 statements about managing CS patients. Results In total, 18 statements reached a consensus. Some relevant unmet needs in the management of CS were reported, mainly related to the lack of a pharmacological treatment successful for the majority of patients. Conclusion While acknowledging the difficulty in achieving complete disease control, a significant change in CS management requires the availability of medical treatment with improved efficacy and safety over available therapeutic options at the time of the current study.
-
7دورية أكاديمية
المؤلفون: Pirchio, R., Auriemma, R. S., Montini, M. E., Vergura, A., Pivonello, R., Colao, A.
المساهمون: Università degli Studi di Napoli Federico II
المصدر: Journal of Endocrinological Investigation ; volume 46, issue 5, page 1027-1038 ; ISSN 1720-8386
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism
الوصف: Purpose Pegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very prolonged PEG treatment are still limited, therefore, we investigated the effects of 10-years PEG on disease control, maximal tumour diameter (MTD), and metabolic profile in consecutive patients resistant to somatostatin analogues (SRLs) followed in an European referral centre for acromegaly. Methods Since the 2000s, we collected data on anthropometric, hormonal and metabolic parameters, and MTD of patients receiving PEG. In the current study, we included 45 patients (19 men, 26 women, 46.8 ± 11 years) treated for at least 5 years with PEG mono or combined therapy, analyzing data before, after 5- and 10-years PEG. Results After10 years, 91% of patients showed full disease control and in 37% a significant decrease in MTD was found. Diabetes prevalence was slightly increased, whereas HbA1c remained stable over the decade. Transaminases remained stable and no case of cutaneous lipohypertrophy was recorded. A different metabolic impact between mono- or combined therapy was found. Patients in monotherapy showed significantly lower fasting glucose ( p = 0.01), fasting insulin ( p = 0.008), HbA1c ( p = 0.007), HOMA-IR ( p = 0.001), and significantly higher ISI 0 ( p = 0.002), whereas patients under combined therapy showed significantly lower total ( p = 0.03), and LDL cholesterol ( p = 0.007). Acromegaly duration before PEG was inversely related to ΔFG ( r = − 0.46, p = 0.03) and ΔFI ( r = − 0.54, p = 0.05). Conclusions PEG is effective and safe in long term. In patients resistant to SRLs, early beginning of PEG allows a wider gluco-insulinemic improvement.
-
8دورية أكاديمية
المؤلفون: Santi D., Lotti F., Sparano C., Rastrelli G., Isidori A. M., Pivonello R., Barbonetti A., Salonia A., Minhas S., Krausz C., Vignozzi L., Maggi M., Corona G.
المساهمون: Santi, D., Lotti, F., Sparano, C., Rastrelli, G., Isidori, A. M., Pivonello, R., Barbonetti, A., Salonia, A., Minhas, S., Krausz, C., Vignozzi, L., Maggi, M., Corona, G.
مصطلحات موضوعية: male fertility, obesity, overweight, semen aparameter, sperm concentration and motility
الوصف: Introduction: Obesity negatively impact on the metabolism of sex hormones, leading to reduced testosterone serum levels. However, how the obesity could negatively impact on the overall gonadal function, particularly on male fertility, remained unclear so far. Objective: To systematically review evidences regarding the influence of body weight excess on the sperm production. Methods: A meta-analysis was conducted, searching all prospective and retrospective observational studies reporting male subjects older than 18 years old, with body weight excess from overweight to severe obesity were considered. Only studies using the V edition of the World Health Organization (WHO) manual for semen analysis interpretation were considered. No specific interventions were considered. Search was focused on studies comparing overweight/obese to normal weight subjects. Results: Twenty-eight studies were considered. Total sperm count and sperm progressive motility were significantly lower in overweight compared to normal weight subjects. Meta-regression analyses demonstrated that patients’ age impacted on sperm parameters. Similarly, obese men showed lower sperm concentration, total sperm number, progressive and total motilities, and normal morphology lower than normal weight subjects. Reduced sperm concentration in obese men was influenced by age, smoking habit, varicocele, and total testosterone serum levels at meta-regression analyses. Conclusions: The male potential fertility is reduced in subjects with increased body weight, compared to normal weight men. The higher was the increased body weight, the worst was the sperm quantity/quality. This result comprehensively included obesity among non-communicable risk factor for male infertility, shedding new lights on the negative impact of increased body weight on overall gonadal function.
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001000690900001; volume:12; issue:1; firstpage:123; lastpage:136; numberofpages:14; journal:ANDROLOGY; https://hdl.handle.net/11588/950916Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85161427675
-
9دورية أكاديمية
المؤلفون: Isidori A. M., Aversa A., Calogero A., Ferlin A., Francavilla S., Lanfranco F., Pivonello R., Rochira V., Corona G., Maggi M.
المساهمون: Isidori A.M., Aversa A., Calogero A., Ferlin A., Francavilla S., Lanfranco F., Pivonello R., Rochira V., Corona G., Maggi M.
الوصف: Purpose To provide the evidence-based recommendations on the role of testosterone (T) on age-related symptoms and signs remains. Methods The Italian Society of Andrology and Sexual Medicine (SIAMS) and the and the Italian Society of Endocrinology (SIE) commissioned an expert task force to provide an updated guideline on adult-onset male hypogonadism. Derived rec ommendations were based on Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. Results Clinical diagnosis of adult-onset hypogonadism should be based on a combination of clinical and biochemical param eters. Testosterone replacement therapy (TRT) should be ofered to all symptomatic subjects with hypogonadism after the exclusion of possible contraindications. T gels and the long-acting injectable T are currently available preparations showing the best efcacy/safety profle. TRT can improve all aspects of sexual function, although its efect is limited in more com plicated patients. Body composition (reducing fat mass and increasing lean mass) is improved after TRT, either in subjects with or without metabolic syndrome or type 2 diabetes. Conversely, the role of TRT in improving glycometabolic control is more conficting. TRT can result in increasing bone mineral density, particularly at lumbar site, but no information on fracture risk is available. Limited data support the use of TRT for improving other outcomes, including mood frailty and mobility. Conclusions TRT can improve sexual function and body composition particularly in less complicated adult and in aging subjects with hypogonadism. When hypogonadism is adequately diagnosed, T appropriately prescribed and subjects cor rectly followed up, no short-term increased risk of adverse events is observed. Longer and larger studies are advisable to better clarify TRT long-term efcacy/safety profle
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36018454; info:eu-repo/semantics/altIdentifier/wos/WOS:000844911500001; volume:45; issue:12; firstpage:2385; lastpage:2403; numberofpages:19; journal:JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION; https://hdl.handle.net/2318/1890644Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85137999958
-
10دورية أكاديمية
المؤلفون: Pasquali D, Chiodini P, Simeon V, Ferlin A, Vignozzi L, Corona G, Lanfranco F, Rochira V, Calogero AE, Bonomi M, Pivonello R, Balercia G, Pizzocaro A, Giagulli VA, Salacone P, Aversa A, Accardo G, Maggi M, Lenzi A, Isidori A, Foresta C, Jannini EA, Garolla A
المساهمون: Pasquali D, Chiodini P, Simeon V, Ferlin A, Vignozzi L, Corona G, Lanfranco F, Rochira V, Calogero AE, Bonomi M, Pivonello R, Balercia G, Pizzocaro A, Giagulli VA, Salacone P, Aversa A, Accardo G, Maggi M, Lenzi A, Isidori A, Foresta C, Jannini EA, Garolla A
الوصف: Background Klinefelter syndrome (KS) is frustratingly under-diagnosed. KS have a broad spectrum of clinical features, making it difficult to identify. Objective We describe KS clinical presentation in a large Italian cohort. Design This is the first observational cohort study within a national network, the Klinefelter ItaliaN Group (KING). Primary outcomes were to describe the basic clinical features and the actual phenotype of KS in Italy. Secondary outcomes were to determine age at diagnosis and geographical distribution. Methods We performed a basic phenotyping and evaluation of the hormonal values of 609 adult KS patients. Results Mean age at diagnosis was 37.4 ± 13.4 years. The overall mean testicular size was 3 ml, and 2.5 ml in both testes in untreated KS group. BMI was 26.6 ± 5.8 kg/m2, and 25.5% of KS had metabolic syndrome (MetS). LH and FSH were increased, and mean total testosterone were 350 ± 9.1 ng/dl. A descriptive analysis showed that 329 KS patients were evaluated in Northern Italy, 76 in Central and 204 in Southern Italy. Analysis of variance demonstrated significant statistical differences (p < 0001) between the age at diagnosis of the three geographical groups. Compared with the expected number among male patients matched for age in Italy, only 16% of KS patients received a diagnosis. Conclusions These data are the results of the only national database available that collects the clinical and hormonal data of the KS patients, currently referred at the KING centers. In Italy the typical KS patient is overweight, with small testes, and elevated LH and FSH. Only 25.5% of them are diagnosed with MetS. Early detection and timely treatment are mandatory.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35608733; info:eu-repo/semantics/altIdentifier/wos/WOS:000801222000002; volume:45; issue:9; firstpage:1769; lastpage:1776; numberofpages:8; journal:JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION; https://hdl.handle.net/2318/1890663Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85135598443
النص الكامل